Sanofi Goes Public With Hostile Medivation Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncology asset fits with CEO Brandicourt's reorganization, but firms like Astellas, AbbVie and AstraZeneca may also be interested.